Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile-Reference-Cited by-同舟云学术

Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile

Published:2017 Issue:4 Volume:8 Page:771-779
ISSN:2040-2503
Container-title:MedChemComm
language:en
Short-container-title:Med. Chem. Commun.

Author:

Futatsugi K.¹²³,Huard K.¹²³,Kung D. W.¹⁴⁵,Pettersen J. C.⁶⁴⁵,Flynn D. A.⁶⁴⁵,Gosset J. R.¹²³,Aspnes G. E.¹²³,Barnes R. J.⁶⁴⁵,Cabral S.¹⁴⁵,Dowling M. S.¹⁴⁵,Fernando D. P.¹⁴⁵,Goosen T. C.¹⁴⁵,Gorczyca W. P.⁶⁴⁵,Hepworth D.¹²³,Herr M.¹⁴⁵,Lavergne S.¹⁴⁵,Li Q.¹⁴⁵,Niosi M.¹⁴⁵,Orr S. T. M.¹⁴⁵,Pardo I. D.⁶⁴⁵,Perez S. M.⁷²³,Purkal J.⁷²³,Schmahai T. J.⁶⁴⁵,Shirai N.⁶⁴⁵,Shoieb A. M.⁶⁴⁵,Zhou J.⁶⁴⁵,Goodwin B.⁷²³

Affiliation:

1. Pfizer Inc. Medicine Design

2. Cambridge

3. 02155 USA

4. Groton

5. 06340 USA

6. Pfizer Inc. Drug Safety Research and Development

7. Pfizer Inc. Cardiovascular and Metabolic Disease Research Unit

Abstract

Preclinical pharmacokinetic, efficacy, and toxicology results are reported for a series of DGAT2 inhibitors for the potential treatment of hypertriglyceridemia.

Funder

Pfizer

Publisher

Royal Society of Chemistry (RSC)

Subject

Pharmaceutical Science,Biochemistry,Drug Discovery,Molecular Medicine,Pharmacology,Organic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2017/MD/C6MD00564K

Reference40 articles.

1. Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults

2. Lipotoxic Diseases

3. Fat in all the wrong places